TrialBritish journal of haematology2018

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.

Elizabeth K O'Donnell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.